Suggested remit - To appraise the clinical and cost effectiveness of lusutrombopag within its marketing authorisation for treating thrombocytopenia in people with chronic liver disease needing elective surgery.
Discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1149
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 February 2023 | Discontinued. Discontinued. |
| 29 November 2018 | Note added to the project documents |
| 26 January 2018 - 23 February 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual